Figure 1. Anti-CD154 and DST interact to protect allogeneic grafts from rejection.
A. B6-Ly5.2/Cr mice were transplanted with BALB/c skin grafts and were treated with 107 BALB/c splenocytes (DST) and/ or anti-CD154 monoclonal antibody (500 μg on D0, 2, 4, 6), where indicated. B. Allo-skin grafts in untreated mice had an MST of 13 days. Monotherapy with either CD40/CD154 pathway blockade or DST led to rapid rejection of the allograft with MSTs of 17.5d (p = 0.039) and 13d (p = n.s.), respectively. Anti-CD154 and DST combined treated significantly prolonged allograft survival to 50 days (p = 0.0002). Data are summary of two experiments of 4–5 mice per group. *p<0.05, ***p<0.001.